• Publications
  • Influence
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.
PURPOSE Standard schedule temozolomide (TMZ; daily for 5 days every 4 weeks) is often used in melanoma patients, but phase III data show that it is no more effective than standard dacarbazine.Expand
  • 229
  • 10
Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.
PURPOSE To perform a double-blind randomized trial with American Joint Commission on Cancer (AJCC) stage III melanoma patients for the following reasons: (1) to confirm our previous finding thatExpand
  • 412
  • 6
Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers.
Defining the expression of tumor-associated antigens on primary and metastatic prostate cancer is the crucial first step in selecting appropriate targets for immune attack. In this study, theExpand
  • 176
  • 6
Antibodies against Tumor Cell Glycolipids and Proteins, but Not Mucins, Mediate Complement-Dependent Cytotoxicity1
One of several effector mechanisms thought to contribute to Ab efficacy against cancer is complement-dependent cytotoxicity (CDC). Serological analysis of a series of clinical trials conducted over aExpand
  • 70
  • 6
Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases.
After 10 years of clinical trials in patients with advanced cancer, monoclonal antibodies (mAbs) against cell surface antigens have not lived up to their initial promise. One such cell surfaceExpand
  • 106
  • 5
Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.
PURPOSE We report the synthesis of a mucin-related O-linked glycopeptide, alpha-N-acetylgalactosamine-O-serine/threonine (Tn), which is highly simplistic in its structure and can induce a relevantExpand
  • 147
  • 4
Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1
Conjugation of antigens to a carrier protein like keyhole limpet hemocyanin (KLH) has proven effective in clinical trials for inducing antibodies against selected tumor antigens. The impact of thisExpand
  • 71
  • 4
Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group‐related antigens
Blood group‐related antigens have been attractive targets for immunotherapy of cancer since their initial identification as cancer‐related antigens. However, available information on the relativeExpand
  • 288
  • 4
Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma.
Increasing doses of saponin fraction QS-21 were administered as immunological adjuvant in a Phase 1 trial with a constant dose of the melanoma ganglioside GM2 covalently attached to keyhole limpetExpand
  • 176
  • 4
Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens.
The relative expression of mucin antigens MUC1, MUC2, MUC3, MUC4, MUC5AC, MUC5B, and MUC7 and glycoprotein antigens KSA, carcinoembryonic antigen, prostate-specific membrane antigen (PSMA),Expand
  • 91
  • 4